ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 199 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,428,284 | +128.7% | 1,023,123 | +338.2% | 0.01% | +200.0% |
Q2 2023 | $4,996,622 | +87667.8% | 233,487 | +65.8% | 0.00% | -33.3% |
Q1 2023 | $5,693 | +118.2% | 140,783 | +151.0% | 0.00% | +200.0% |
Q4 2022 | $2,609 | -99.9% | 56,083 | +49.2% | 0.00% | 0.0% |
Q3 2022 | $1,949,000 | +79.8% | 37,584 | +63.9% | 0.00% | 0.0% |
Q2 2022 | $1,084,000 | -79.9% | 22,936 | -69.7% | 0.00% | -50.0% |
Q1 2022 | $5,391,000 | +355.3% | 75,733 | +378.4% | 0.00% | +100.0% |
Q4 2021 | $1,184,000 | +34.4% | 15,832 | +2.1% | 0.00% | 0.0% |
Q3 2021 | $881,000 | -85.8% | 15,501 | -89.0% | 0.00% | -75.0% |
Q2 2021 | $6,194,000 | +426.7% | 140,742 | +490.2% | 0.00% | +300.0% |
Q1 2021 | $1,176,000 | -84.2% | 23,845 | -86.5% | 0.00% | -80.0% |
Q4 2020 | $7,442,000 | +29.1% | 176,769 | +40.4% | 0.01% | -28.6% |
Q3 2020 | $5,764,000 | +211.2% | 125,913 | +241.3% | 0.01% | +133.3% |
Q2 2020 | $1,852,000 | -55.1% | 36,887 | -54.0% | 0.00% | -66.7% |
Q1 2020 | $4,124,000 | +78.3% | 80,183 | +114.2% | 0.01% | +200.0% |
Q4 2019 | $2,313,000 | +586.4% | 37,432 | +565.9% | 0.00% | +200.0% |
Q3 2019 | $337,000 | -93.9% | 5,621 | -91.4% | 0.00% | -87.5% |
Q2 2019 | $5,514,000 | -63.0% | 65,352 | -58.1% | 0.01% | -63.6% |
Q1 2019 | $14,898,000 | +919.0% | 155,970 | +655.5% | 0.02% | +1000.0% |
Q4 2018 | $1,462,000 | +197.2% | 20,645 | +386.2% | 0.00% | +100.0% |
Q2 2018 | $492,000 | -93.3% | 4,246 | -95.3% | 0.00% | -90.0% |
Q1 2018 | $7,307,000 | -43.6% | 90,316 | -59.1% | 0.01% | -44.4% |
Q4 2017 | $12,959,000 | -26.1% | 220,845 | -54.7% | 0.02% | -41.9% |
Q2 2017 | $17,537,000 | +29.1% | 487,405 | +10.5% | 0.03% | +24.0% |
Q1 2017 | $13,580,000 | +327.7% | 440,901 | +365.2% | 0.02% | +257.1% |
Q4 2016 | $3,175,000 | -26.4% | 94,774 | -41.5% | 0.01% | 0.0% |
Q3 2016 | $4,314,000 | +360.4% | 162,118 | +281.4% | 0.01% | +250.0% |
Q2 2016 | $937,000 | -88.5% | 42,510 | -84.1% | 0.00% | -86.7% |
Q1 2015 | $8,173,000 | +1505.7% | 266,927 | +2569.3% | 0.02% | +1400.0% |
Q4 2014 | $509,000 | -77.4% | 10,000 | -82.4% | 0.00% | -83.3% |
Q3 2014 | $2,248,000 | +864.8% | 56,813 | +949.2% | 0.01% | +500.0% |
Q2 2014 | $233,000 | -92.1% | 5,415 | -95.0% | 0.00% | -88.9% |
Q4 2013 | $2,933,000 | – | 107,519 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |